Results 31 to 40 of about 15,373 (177)

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

Journal of Global Oncology, 2017
Purpose: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a ...
Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro   +14 more
doaj   +1 more source

Quality of life with palbociclib plus fulvestrant placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Therapeutic Advances in Medical Oncology, 2023
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC).
Ariadna Tibau, M. Teresa Martínez, Manuel Ramos, Luis De La Cruz-Merino, Ana Santaballa, Miriam O’Connor, Noelia Martínez-Jañez, Fernando Moreno, Isaura Fernández, Juan Antonio Virizuela, Jesús Alarcón, Juan de La Haba-Rodríguez, Pedro Sánchez-Rovira, Cinta Rosa Albacar, Coralia Bueno Muiño, Catherine Kelly, Maribel Casas, Susana Bezares, Libertad Rosell, Joan Albanell   +19 more
doaj   +1 more source

Fulvestrant in hormonal treatment of breast cancer [PDF]

, 2017
Fulvestrant is a selective oestrogen receptor (ER) down-regulator (SERD), which lacks partial agonistic properties characteristic for selective oestrogen receptor modulators (SERM).
Potemski, Piotr; Klinika Chemioterapii Nowotworów, Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi, Zięba, Agnieszka; Klinika Chemioterapii Nowotworów, Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi, Dębska-Szmich, Sylwia; Chemotherapy Clinic, Oncology Department, Medical University of Lodz, Poland; Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Lodz, Poland   +2 more
core   +1 more source

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer [PDF]

, 2018
BACKGROUND The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2 ...
Verma, S., Harbeck, N., Loi, S., André, F., Ro, J., Turner, N.C., Huang, X., Huang Bartlett, C., Masuda, N., Iwata, H., Slamon, D.J., Giorgetti, C., Cristofanilli, M., Bondarenko, I., Colleoni, M., Puyana Theall, K., Loibl, S., Im, S.-A., DeMichele, A.   +18 more
core   +2 more sources

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

BMC Cancer, 2023
Background This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (
Yiyuan Liu, Jinyao Wu, Zeqi Ji, Lingzhi Chen, Juan Zou, Jiehua Zheng, Weixun Lin, Jiehui Cai, Yaokun Chen, Daitian Zheng, Yexi Chen, Zhiyang Li   +11 more
doaj   +1 more source

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice

Медицинский совет, 2021
Introduction. Сombination of alpelisib plus fulvestrant is approved in patients with hormone receptor positive, HER2-negative, PIK3CA-mutated advanced breast cancer (ABC) after progression on hormonotherapy.
D. A. Filonenko, T. M. Ibragimova, N. I. Polshina, A. V. Belogurova, E. I. Khatkova, E. A. Arutiunian, E. I. Volkova, L. G. Zhukova   +7 more
doaj   +1 more source

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance

Molecular Oncology, 2016
Fulvestrant is a dose dependent selective estrogen receptor (ER) down‐regulator (SERD) used in ER‐positive metastatic breast cancer (MBC). Nearly all patients develop resistance.
Costanza Paoletti, Jose M. Larios, Maria C. Muñiz, Kimberly Aung, Emily M. Cannell, Elizabeth P. Darga, Kelley M. Kidwell, Dafydd G. Thomas, Nahomi Tokudome, Martha E. Brown, Mark C. Connelly, David A. Chianese, Anne F. Schott, N. Lynn Henry, James M. Rae, Daniel F. Hayes   +15 more
doaj   +1 more source

Fulvestrant for the treatment of advanced breast cancer [PDF]

, 2018
Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader
Blackburn, Sophie A., Kwok-Leung Cheung, Cheung, Kwok-Leung, Ruth M. Parks, Parks, Ruth M., Sophie A. Blackburn   +5 more
core   +1 more source

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Nature Communications, 2016
Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome of ...
Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian Krop, Peter Schmid, Mark R. Lackner   +15 more
doaj   +1 more source

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients

Journal of Translational Medicine, 2019
Background Among breast cancer (BC) patients, near 40% are post-menopause, and 70%–80% are hormone receptor (HR)-positive. About 30%–40% BC patients who are diagnosed as invasive carcinoma HR-positive BC would eventually develop metastatic breast cancers.
Jingyu Liu, Jing Li, Hui Wang, Yikai Wang, Qiongzhi He, Xuefeng Xia, Zhe-Yu Hu, Quchang Ouyang   +7 more
doaj   +1 more source